Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ETX2514 in Healthy Subjects
NCT02971423Phase 1Completed
- Sponsor
- Entasis Therapeutics
- Start
- Oct 2016
- Primary completion
- Jun 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of durlobactam in Acinetobacter baumannii infection (15 cohorts), sponsored by Entasis Therapeutics. Primary endpoints: Number of participants with any non-serious and any serious adverse event, Number of participants with abnormal, clinically significant hematology and clinical chemistry laboratory values at Day 25 and 11 more. Started Oct 2016; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT02971423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971423.